KRAS G12D is a mutation of the KRAS gene that can lead to uncontrolled cell growth and aggressive cancers: Prevalence KRAS G12D is present in more than one in three pancreatic cancers, about one in ten colorectal cancers, and in several other cancer types.
Clinical impact KRAS G12D is associated with worse outcomes, including increased rates of distant recurrence. People with KRAS mutations generally have lower life expectancy than those without the mutation. Treatments KRAS G12D is a predictive biomarker for certain drugs, including afatinib, dacomitinib, erlotinib, gefitinib, osimertinib, cetuximab, and panitumumab. For KRAS-mutant non-small cell lung cancer (NSCLC), the standard first-line treatment is immunotherapy alone or in combination with platinum-based chemotherapy.
KRAS gene The KRAS gene plays a critical role in cell signaling pathways that control cell growth and division.
KRAS G12D is a mutation of the KRAS gene that can lead to uncontrolled cell growth and aggressive cancers: Prevalence KRAS G12D is present in more than one in three pancreatic cancers, about one in ten colorectal cancers, and in several other cancer types.
Clinical impact KRAS G12D is associated with worse outcomes, including increased rates of distant recurrence. People with KRAS mutations generally have lower life expectancy than those without the mutation.
Treatments KRAS G12D is a predictive biomarker for certain drugs, including afatinib, dacomitinib, erlotinib, gefitinib, osimertinib, cetuximab, and panitumumab. For KRAS-mutant non-small cell lung cancer (NSCLC), the standard first-line treatment is immunotherapy alone or in combination with platinum-based chemotherapy.
KRAS gene The KRAS gene plays a critical role in cell signaling pathways that control cell growth and division.
国内医生会建议的
不过似乎都在临床试验阶段
申请参加临床试验
80岁了就保守治疗提高生活质量吧